Spero Therapeutics (SPRO) – Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Spero Therapeutics (NASDAQ: SPRO):

  • 2/8/2018 – Spero Therapeutics is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $27.00 price target on the stock. They wrote, “Differentiated pipeline addresses large unmet needs in infectious disease. Spero has three development programs that target multibillion-dollar commercial opportunities. The company’s drugs focus on unmet needs inside and outside the hospital setting. Spero plans to commercialize its products using an accelerated path to market, saving investors time and money. The company’s three leading drugs: 1) SPR994/oral carbapenem, which could be the first new oral therapy for cUTI in 21 years. Unlike competing drugs, SPR994 will be covered outside the hospital formulary, where it will not compete with generics and be part of the bundle. The drug is being developed for UTI, but could also be used for IAI, blood stream infections, and CAP; 2) SPR741 and SPR206/IV potentiators address major unmet needs in the hospital setting and expand the utility of existing antibiotics; and, 3) the SPR720/NTM program is a novel oral bacterial gyrase inhibitor designed to treat a rare lung infection.””
  • 2/2/2018 – Spero Therapeutics was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 1/31/2018 – Spero Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. “
  • 1/30/2018 – Spero Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $14.00 price target on the stock. According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. “
  • 1/11/2018 – Spero Therapeutics was given a new $30.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 12/18/2017 – Spero Therapeutics was given a new $30.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.

Shares of Spero Therapeutics Inc (SPRO) opened at $11.20 on Wednesday. The company has a market capitalization of $160.93 and a P/E ratio of -3.93. Spero Therapeutics Inc has a 1-year low of $9.84 and a 1-year high of $15.40.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Thursday, December 14th. The company reported ($36.02) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.43) by ($33.59). The firm had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $0.20 million. equities analysts forecast that Spero Therapeutics Inc will post -8.52 earnings per share for the current fiscal year.

Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720.

Receive News & Ratings for Spero Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply